Mitomycin C treatment induces resistance and enhanced migration via phosphorylated Akt in aggressive lung cancer cells

Since 1984, mitomycin C (MMC) has been applied in the treatment of non-small-cell lung cancer (NSCLC). MMC-based chemotherapeutic regimens are still under consideration owing to the efficacy and low cost as compared with other second-line regimens in patients with advanced NSCLC. Hence, it is import...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Cheng-Ying, Chen, Li-Han, Lin, Yu-Fen, Lai, Liang-Chuan, Chuang, Eric Y., Tsai, Mong-Hsun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346766/
https://www.ncbi.nlm.nih.gov/pubmed/27833080
http://dx.doi.org/10.18632/oncotarget.13237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346766/
https://www.ncbi.nlm.nih.gov/pubmed/27833080
http://dx.doi.org/10.18632/oncotarget.13237

Ejemplares similares